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Abstract — Prion diseases are incurable and fatal neurodegenerative disorders that affect both humans and 
animals. The causative agent is an infectious protein called prion (PrPSc), which is the pathological form of a 
normal protein (PrPC) present on the cell membrane. The molecular mechanisms underlying prion replication 
and subsequent degeneration of the Central Nervous System (CNS) are still poorly understood and therefore 
innovative approaches are needed to build diagnostic, therapeutic, taxonomic, and disease surveillance tools. 
We adopted an unbiased genomic approach and conducted whole transcriptome analyses using microarray 
and RT-qPCR gene expression methods in brain of infected macaques versus healthy controls. We identified a 
set of genes that could become novel biomarkers for early diagnosis and/or therapeutic strategies for prion 
diseases and other neurodegenerative disorders.
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_____________________________________________________________________ 
1 BACKGROUND
Prion diseases are fatal neurodegenerative disorders that affect humans and animals. Their pathogenesis 
mechanisms are not fully understood and there is no diagnostic tool, nor a cure for them [1]. Among 
these disorders, the best known to the general public is the Bovine Spongiform Encephalopathy (BSE) or 
“mad cow disease” with the related human form called variant Creutzfeldt-Jakob Disease (vCJD). In this 
context, the analysis of gene expression alterations occurring in prion-infected animal models represents 
a powerful tool that may contribute to unravel the molecular basis of prion diseases and therefore 
discover novel potential targets for diagnosis and therapeutics. 
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2 OBJECTIVES
The goal of our project is identifying differentially expressed genes in infected animals versus controls 
that can become potential targets for diagnostic and/or therapeutic approaches. 
Recent findings support the idea that neurodegenerative diseases may all share a common 
mechanism that implies a prion-like behavior. Therefore, even though prion diseases are rare disorders, 
basic research on their mechanisms may be useful to explain all the neurodegenerative maladies, like 
Alzheimer’s and Parkinson’s diseases, that affect large portions of the world population.
3 APPROACH & METHODS
General approach
We performed for the first time a large-scale gene expression profiling of brains from BSE-infected 
macaques, an excellent model for human prion disorders.
Methods
We performed an mRNA expression analysis using microarrays  with subsequent validation of selected 
targets by RT-qPCR. mRNA was extracted from brain frontal cortex (superior frontal gyrus)  of 6 
intracranially BSE-infected animals (A1 to A6) and 5 non infected controls (CovA, CovB, CovC, CovDI, 
CovDII). All samples were analyzed using the GeneChip® Rhesus Macaque Genome Array (Affymetrix®) 
that contains 52,024 rhesus probe sets to enable gene expression studies of Macaca mulatta 
transcriptome interrogating more than 47,000 transcripts. RT-qPCR was performed using SYBR® Green-
based assays (Bio-Rad Laboratories, Inc.) and then TaqMan® MGB probes (Life Technologies) at a later 
stage for results confirmation. 
4 RESULTS
The microarray analysis revealed about 300 transcripts with expression changes around twofold. 
Among these, the Gene Ontology analysis identified 86 genes with known functions, most of which are 
involved in cellular development, cell death and survival, lipid homeostasis, and acute phase response 
signaling. 12 of these genes were analyzed by RT-qPCR and the regulation trend was confirmed. In 
particular, a 5 gene signature was identified in infected vs. control animals with statistical significance. 
These genes are involved in oxygen or lipid transport and in innate immunity as well as inflammatory 
response. These genes are known to be deregulated in other neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases. Their protein products may become potential targets for both 
general diagnosis and therapeutic purposes of many neurodegenerative diseases.
 
143
Figure 1: Condition trees of the clustering analysis
The hierarchical cluster analysis (Euclidean distance clustering algorithm) was performed using “R” and Partek® 
Software (Partek Inc.): 86 clones/genes showed a differential expression. Each colored bar represents a gene. The 
color represents the level of expression (red: up-regulation, blue: down-regulation) and the sample information 
is listed across the bottom. The names of the known genes are indicated on the right handside. A picture of a 
representative Affymetrix chip is captured on the upper right corner.
Figure 2: SYBR® Green-based RT-qPCR validation of microarray results 
Validation by RT-qPCR was performed using gene-specific primer pairs and cDNA synthesis was accomplished 
using 100 ng RNA per sample. The relative expression ratio was calculated using the ΔΔCT method and significance 
was calculated with the unpaired student t-test (p < 0.05).  Among the 12 genes analyzed, 5 were found to be 
differentially regulated: 2 were down-regulated (HBA2 and HBB) and 3 were up-regulated (TTR, APOC1,SERPINA3) 
(green squares) with statistical significance [2].
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5 POTENTIAL NEW PRODUCTS & SERVICES
Product 1: A qPCR-based diagnostic test for neurodegenerative diseases. We can conceive a microtiter 
plate containing lyophylized probes for the identified markers; patient samples will be added (brain 
biopsies, liquor, blood) and qPCR will be performed .
Product 2: An antibody-based diagnostic test for neurodegenerative diseases: major work is needed to 
validate the differential expression of these targets at protein level and in additional  tissues more easily 
accessible than brain (e.g., liquor, blood). The  antibodies will be absorbed on the microtiter plate and 
a colorimetric reaction will happen after adding the patient sample.
6 CURRENT COLLABORATIONS
6.1 With other researchers 
Dirk Motzkus, Unit of Infection Models, German Primate Center, Göttingen, Germany; 
Uroš Rajčević and Vladka Čurin Šerbec, BTCS, Ljubljana, Slovenia (PP10) 
6.2 With hospitals 
Policlinico and University of Verona, Italy; Fondazione IRCCS Istituto  Neurologico Carlo Besta, Milan, 
Italy
7 CONTACT OR COLLABORATIONS NEEDED
Hospitals: access to diseased human samples and controls
Proteomics research centers: validation at protein level
Diagnostic companies: development of IVD/GMP/FDA-approved reagents and kits
8 COMMUNICATION TOOLS
Scientific publications
Barbisin M, Vanni S, Schmädicke AC , Motzkus D, Opitz L, Salinas-Riester G, Legname G. Gene expression 
profiling of brains from bovine spongiform encephalopathy (BSE)-infected cynomolgus macaques. 
BMC Genomics, 15:434, 2014.
Conference poster
Schmädicke AC , Barbisin M, Motzkus D, Opitz L, Gasperini L., Salinas-Riester G, Vanni S,  Legname G. 
Whole transcriptome analysis in brains from BSE-infected macaques. Prion 2012, Amsterdam, May 9-12 
2012.
Dissemination workshop
Barbisin M, Legname G. Gene expression profiling of BSE-infected macaques. Molecular tools to study 
neurodegeneration, Trieste, Sep 19 2013.
Media
http://it.linkedin.com/pub/maura-barbisin/2/6a3/598
https://www.facebook.com/maura.barbisin
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9 FUNDS NEEDED
9.1 For basic research (investigation of biological mechanisms): € 100,000.00
9.2 For applied research (solutions for real-world problems): € 300,000.00
9.2 For pilot & demonstrator activities (to develop a prototype): € 500,000.00
10 CONCLUSION
To our knowledge, this is the first genome-wide expression study in frontal cortex of macaques 
inoculated with BSE. Using microarray and RT-qPCR technologies we identified a gene signature able 
to distinguish infected macaques from control animals. These results could be extremely helpful in 
understanding the progression of the disease, allowing for the identification of some key players 
which, if not being the cause of the onset, could be some of the target genes affected by the disease. 
Our animal model is the closest available model for human vCJD and these results, obtained with an 
unbiased methodology as the gene expression microarray technology, are contributing to shed some 
light on the molecular basis of prion diseases as well as neurodegeneration as a whole.
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